| pubmed-article:7781714 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7781714 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7781714 | lifeskim:mentions | umls-concept:C0023884 | lld:lifeskim |
| pubmed-article:7781714 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:7781714 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:7781714 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:7781714 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7781714 | pubmed:dateCreated | 1995-7-14 | lld:pubmed |
| pubmed-article:7781714 | pubmed:abstractText | The alpha 1-adrenoceptor subtype present in human liver membranes was studied using radioligand binding techniques. [3H]Prazosin binding was rapid, saturable and reversible. A kinetically derived Kd of 0.22 nM was obtained. Rosenthal analysis of saturation isotherms indicated a single class of binding sites with a Kd of 0.47 nM and a Bmax of 70 fmol/mg of protein. Membrane preincubation with chloroethylclonidine markedly decreased total binding (62% decrease) without altering the Kd for the radioligand. Binding competition experiments were performed and the order of potency for agonists was: oxymetazoline > epinephrine > or = norepinephrine > methoxamine. The binding affinity for epinephrine was modulated by the GTP analogue guanosine-5'-(beta,gamma-imido)triphosphate. For antagonists the potency order was: WB4101 > or = prazosin > or = (+)-niguldipine = 5-methylurapidil > or = benoxathian > or = phentolamine. The pharmacological profile of the [3H]prazosin binding sites of human liver membranes suggests that alpha 1A-adrenoceptors predominate (75%-85% of the alpha 1-adrenoceptors) in this tissue. | lld:pubmed |
| pubmed-article:7781714 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7781714 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7781714 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7781714 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7781714 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7781714 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7781714 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:7781714 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:7781714 | pubmed:author | pubmed-author:García-SáinzJ... | lld:pubmed |
| pubmed-article:7781714 | pubmed:author | pubmed-author:Romero-AvilaM... | lld:pubmed |
| pubmed-article:7781714 | pubmed:author | pubmed-author:Tórres-Márque... | lld:pubmed |
| pubmed-article:7781714 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7781714 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7781714 | pubmed:volume | 289 | lld:pubmed |
| pubmed-article:7781714 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7781714 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7781714 | pubmed:pagination | 81-6 | lld:pubmed |
| pubmed-article:7781714 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:meshHeading | pubmed-meshheading:7781714-... | lld:pubmed |
| pubmed-article:7781714 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7781714 | pubmed:articleTitle | Characterization of the human liver alpha 1-adrenoceptors: predominance of the alpha 1A subtype. | lld:pubmed |
| pubmed-article:7781714 | pubmed:affiliation | Departamento de Bioenergética, Universidad Nacional Autónoma de México, México, D.F. | lld:pubmed |
| pubmed-article:7781714 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7781714 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:7781714 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7781714 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7781714 | lld:pubmed |
